Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02162849 · ClinicalTrials.gov registry record · Phase 4
Reward Sensitivity and Pharmacotherapy for Smoking Cessation
A Phase 4 study of Tobacco Use Cessation, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 4
- Development phase
- 204
- Enrollment target
- 1
- Study location
NCT02162849: Active Phase 4 study of Tobacco Use Cessation, sponsored by M.D. Anderson Cancer Center.
NCT02162849 is a Phase 4 study of Tobacco Use Cessation that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 204 participants, below the 879-participant average among 36 other Tobacco Use Cessation trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02162849, a Phase 4 study of Tobacco Use Cessation, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 204 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is learn if varenicline or the nicotine patch can help people with different types of emotion and attention levels to quit smoking.
Primary Outcome
Continuous abstinence over the last 4 weeks of treatment (i.e. EOT-end of treatment) will serve as the primary outcome measure. Saliva will be collected to measure cotinine level.
Conditions Studied
Interventions
- BEHAVIORAL Questionnaires
- DRUG Varenicline
- DRUG Nicotine Patch
- DRUG Placebo Patch
- DRUG Placebo Tablet
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2015-12-14 |
| Est. Completion | 2028-02-28 |
| Phase | Phase 4 |
What the registry record for NCT02162849 still lists
NCT02162849 is an interventional study that assigns participants to a tested intervention. The registered 204 participants enrollment target is mid-sized for trials with a published cap, below the 879-participant average among 36 other Tobacco Use Cessation trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Tobacco Use Cessation appearing as the primary indexed condition, and to 5 interventions - of which Questionnaires is the first listed.
NCT02162849 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02162849 about?
NCT02162849 is a clinical study titled "Reward Sensitivity and Pharmacotherapy for Smoking Cessation". The goal of this clinical research study is learn if varenicline or the nicotine patch can help people with different types of emotion and attention levels to quit smoking.
What is the current status of trial NCT02162849?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 204 participants. The study started on 2015-12-14. Estimated completion is 2028-02-28.
What conditions does trial NCT02162849 study?
This clinical trial studies the following conditions: Tobacco Use Cessation.
What interventions are being tested in trial NCT02162849?
The interventions under investigation include: Questionnaires (BEHAVIORAL), Varenicline (DRUG), Nicotine Patch (DRUG), Placebo Patch (DRUG), Placebo Tablet (DRUG).
Who is sponsoring clinical trial NCT02162849?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02162849 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tobacco Use Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02162849's enrollment target sits among peer trials
204 19th of 36 higher than 18 of 36 other Tobacco Use Cessation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tobacco Use Cessation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Extended Intervention for Tobacco Use (EXIT) for People Experiencing Homelessness
RECRUITING · Phase 4
-
Smoking Cessation Program in the Construction Sector
RECRUITING · Phase 4
-
Engagement With an Adaptive Mobile Health Smoking Cessation Intervention
COMPLETED · Phase 4
-
A Smart Approach to Treating Tobacco Use Disorder in Persons Living With HIV
COMPLETED · Phase 4
-
Cannabis-Tobacco Co-Use Treatment Study
RECRUITING · Phase 3
-
Reach Through Equitable Implementation in Utah
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03481010 · 204 participants · NA
Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology
- NCT04249830 · 204 participants · NA
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults
- NCT04503395 · 204 participants · NA
ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES
- NCT04793776 · 204 participants · NA
Manage Emotions to Reduce Aggression (MERA)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI